LT2300455T - 2-fluor-n-metil-4-[7-(chinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamido druskos ir su jų gamyba susiję būdai - Google Patents

2-fluor-n-metil-4-[7-(chinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamido druskos ir su jų gamyba susiję būdai

Info

Publication number: LT2300455T
Authority: LT; Lithuania
Prior art keywords: methyl; triazin; quinolin; imidazo; benzamide
Prior art date: 2008-05-21

Application number

LTEP09751439.2T

Other languages

English (en)

Inventor

Lingkai Weng

Lei Qiao

Jiacheng Zhou

Pingli Liu

Yongchun Pan

Original Assignee

Incyte Holdings Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-21

Filing date

2009-05-20

Publication date

2017-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41058602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2300455(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-20 Application filed by Incyte Holdings Corporation filed Critical Incyte Holdings Corporation

2017-11-10 Publication of LT2300455T publication Critical patent/LT2300455T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)

LTEP09751439.2T 2008-05-21 2009-05-20 2-fluor-n-metil-4-[7-(chinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamido druskos ir su jų gamyba susiję būdai LT2300455T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5499508P	2008-05-21	2008-05-21
PCT/US2009/044622 WO2009143211A2 (en)	2008-05-21	2009-05-20	Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same

Publications (1)

Publication Number	Publication Date
LT2300455T true LT2300455T (lt)	2017-11-10

Family

ID=41058602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP09751439.2T LT2300455T (lt)	2008-05-21	2009-05-20	2-fluor-n-metil-4-[7-(chinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamido druskos ir su jų gamyba susiję būdai

Country Status (30)

Country	Link
US (7)	US8420645B2 (lt)
EP (2)	EP3287449A3 (lt)
JP (2)	JP6022158B2 (lt)
KR (1)	KR101706784B1 (lt)
CN (4)	CN102083814B (lt)
AR (3)	AR071873A1 (lt)
BR (1)	BRPI0912882A2 (lt)
CA (1)	CA2724742C (lt)
CL (1)	CL2009001250A1 (lt)
CO (1)	CO6300934A2 (lt)
CY (1)	CY1119813T1 (lt)
DK (1)	DK2300455T3 (lt)
EA (1)	EA021364B1 (lt)
EC (1)	ECSP10010685A (lt)
ES (1)	ES2643363T3 (lt)
HK (1)	HK1251568A1 (lt)
HR (1)	HRP20171528T1 (lt)
HU (1)	HUE034716T2 (lt)
IL (3)	IL209229A (lt)
LT (1)	LT2300455T (lt)
MA (1)	MA32405B1 (lt)
MX (3)	MX2010012718A (lt)
MY (3)	MY155565A (lt)
NZ (2)	NZ589622A (lt)
PL (1)	PL2300455T3 (lt)
PT (1)	PT2300455T (lt)
SI (1)	SI2300455T1 (lt)
TW (1)	TWI472529B (lt)
WO (1)	WO2009143211A2 (lt)
ZA (1)	ZA201008212B (lt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3034075T3 (en)	2006-11-22	2018-10-22	Incyte Holdings Corp	IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASEI INHIBITORS
LT2300455T (lt)	2008-05-21	2017-11-10	Incyte Holdings Corporation	2-fluor-n-metil-4-[7-(chinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamido druskos ir su jų gamyba susiję būdai
MX2012008898A (es) *	2010-02-03	2012-11-06	Incyte Corp	Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
BR112014006223A8 (pt)	2011-09-15	2018-01-09	Novartis Ag	3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
DE102013100596B4 (de)	2012-01-27	2023-09-07	Samsung Electronics Co. Ltd.	Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren
CA2868202C (en) *	2012-04-03	2021-08-10	Novartis Ag	Combination products with tyrosine kinase inhibitors and their use
IN2015DN00528A (lt) *	2012-08-16	2015-06-26	Novartis Ag
PT2976106T (pt)	2013-03-21	2021-05-26	Array Biopharma Inc	Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102442436B1 (ko)	2014-03-14	2022-09-15	노파르티스 아게	Lag-3에 대한 항체 분자 및 그의 용도
CN115364061A (zh)	2014-07-25	2022-11-22	诺华股份有限公司	C-met抑制剂的片剂制剂
WO2016011658A1 (en) *	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
WO2016016822A1 (en)	2014-07-31	2016-02-04	Novartis Ag	Combination therapy
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en)	2014-10-14	2017-04-27	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
JO3746B1 (ar)	2015-03-10	2021-01-31	Aduro Biotech Inc	تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
JP6878405B2 (ja)	2015-07-29	2021-05-26	ノバルティスアーゲー	Ｐｄ−１に対する抗体分子を含む組み合わせ治療
SI3317301T1 (sl)	2015-07-29	2021-10-29	Novartis Ag	Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017106656A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
MX2018009252A (es)	2016-01-27	2019-01-21	Univ Zuerich	Uso de moduladores de receptores de gabaa para el tratamiento de picor.
WO2018009466A1 (en)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496000A (zh) *	2016-10-19	2017-03-15	蚌埠学院	一种3‑氟‑4‑溴‑苯乙酮的合成方法
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
EP3641812A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
KR20210011921A (ko)	2018-04-18	2021-02-02	뉴로사이클 테라퓨틱스, 인크.	Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도
CN110526916B (zh) *	2018-05-23	2021-07-13	海创药业股份有限公司	氘代Capmatinib化合物及其用途
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
CN114364798A (zh)	2019-03-21	2022-04-15	欧恩科斯欧公司	用于治疗癌症的Dbait分子与激酶抑制剂的组合
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
WO2021165818A1 (en) *	2020-02-17	2021-08-26	Novartis Ag	Process and intermediates for the preparation of 2-fluoro-n-methyl-4-[7-quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2yl]benzamide
US20230263795A1 (en) *	2020-06-02	2023-08-24	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
CN111825678A (zh) *	2020-06-05	2020-10-27	连庆泉	一种卡马替尼的制备方法
WO2022007752A1 (zh) *	2020-07-06	2022-01-13	苏州晶云药物科技股份有限公司	苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
WO2022063869A2 (en) *	2020-09-24	2022-03-31	Merck Patent Gmbh	Compounds for the treatment of viral infections
CN112480017A (zh) *	2020-11-13	2021-03-12	金仓(上海)医药生物科技有限公司	一种3-氨基-1,2,4-三嗪的制备方法
CA3224341A1 (en)	2021-09-01	2023-03-09	Novartis Ag	Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN113896732B (zh) *	2021-10-13	2023-09-12	沈阳红旗制药有限公司	抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) *	2022-06-22	2023-12-28	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1411859A (en)	1920-12-08	1922-04-04	Marchand Robert	Process for preparing hydrate of terpin
US2837520A (en) *	1955-05-26	1958-06-03	Ind Chimica Profarmaco S R L	Fluorescent materials on the basis of tetrazoindenes
US4220450A (en)	1978-04-05	1980-09-02	Syva Company	Chemically induced fluorescence immunoassay
US4209621A (en) *	1979-04-27	1980-06-24	American Cyanamid Company	(Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en)	1981-09-02	1983-09-20	Diamond Shamrock Corporation	Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de)	1983-03-31	1984-10-04	Hoechst Ag, 6230 Frankfurt	Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
DE3421029C2 (de)	1984-06-06	1986-04-24	Walter Steinhausen Mathis	Verfahren und Vorrichtung zum trockenen Bedrucken eines Werkstückes unter Verwendung einer Heißprägefolie
JPS6337347A (ja)	1986-08-01	1988-02-18	Fuji Photo Film Co Ltd	直接ポジカラ−画像形成方法
JPS63199347A (ja)	1987-02-14	1988-08-17	Konica Corp	鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja)	1987-06-12	1988-12-19	Yoshitomi Pharmaceut Ind Ltd	縮合ピリダジン化合物
US5236917A (en) *	1989-05-04	1993-08-17	Sterling Winthrop Inc.	Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja)	1989-06-12	1991-01-22	Konica Corp	ハロゲン化銀写真感光材料
IL96432A0 (en)	1989-11-30	1991-08-16	Schering Ag	Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja)	1990-02-15	1997-10-15	富士写真フイルム株式会社	ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr)	1990-05-16	1991-11-22	Lipha	Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja)	1991-01-09	1992-09-07	Konica Corp	ハロゲン化銀写真感光材料
FR2671551B1 (fr) *	1991-01-15	1993-03-12	Adir	Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05232618A (ja)	1992-02-21	1993-09-10	Konica Corp	ハロゲン化銀写真感光材料
DE4309285A1 (de)	1993-03-23	1994-09-29	Boehringer Ingelheim Kg	Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
ES2137113B1 (es)	1997-07-29	2000-09-16	Almirall Prodesfarma Sa	Nuevos derivados de triazolo-piridazinas heterociclicos.
JP4251243B2 (ja)	1998-11-26	2009-04-08	株式会社日立メディコ	領域拡張装置
JP4025468B2 (ja)	1999-07-29	2007-12-19	三井化学株式会社	有機電界発光素子
ID29514A (id)	1999-11-10	2001-09-06	Ortho Mcneil Pharmacetical Inc	2-ARIL-3-(HETEROARIL)-IMIDAZO [1,2-a]PIRIMIDIN TERSUBSTITUSI, DAN METODE-METODE DAN KOMPOSISI-KOMPOSISI FARMASI YANG TERKAIT
MXPA02004735A (es)	1999-11-12	2003-01-28	Orive Javier Uhthoff	Compuestos heteroaromaticos, biciclicos y triciclicos.
CN1321628C (zh)	2000-06-28	2007-06-20	史密斯克莱·比奇曼公司	湿磨方法
WO2002072579A1 (en)	2001-03-09	2002-09-19	Pfizer Products Inc.	Triazolopyridines as anti-inflammatory agents
GB0107751D0 (en)	2001-03-28	2001-05-16	Pfizer Ltd	Pharmaceutically active compounds
KR20040000507A (ko)	2001-05-24	2004-01-03	야마노우치세이야쿠 가부시키가이샤	3-퀴놀린-2(1ｈ)-일리덴인돌린-2-온 유도체
WO2003074525A1 (fr) *	2002-03-01	2003-09-12	Yamanouchi Pharmaceutical Co., Ltd.	Compose heterocyclique azote
WO2003080621A1 (en)	2002-03-19	2003-10-02	Merck & Co., Inc.	Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en)	2002-04-18	2004-09-14	Hoffmann-La Roche Inc.	2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210127D0 (en) *	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
GB0210124D0 (en) *	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
DE10230604A1 (de)	2002-07-08	2004-01-29	Bayer Ag	Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de)	2002-07-08	2004-01-29	Bayer Ag	Substituierte Imidazotriazine
PA8580301A1 (es) *	2002-08-28	2005-05-24	Pfizer Prod Inc	Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
CA2496812A1 (en)	2002-08-30	2004-03-11	Pfizer Products Inc.	Novel processes and intermediates for preparing triazolo-pyridines
US6784297B2 (en)	2002-09-04	2004-08-31	Kopran Limited	Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
NZ541151A (en)	2002-12-18	2008-09-26	Vertex Pharma	Triazolopyridazines as protein kinase inhibitors
WO2005002590A1 (ja)	2003-07-01	2005-01-13	Astellas Pharma Inc.	骨量増加誘導剤
US7230098B2 (en)	2003-02-26	2007-06-12	Sugen, Inc.	Aminoheteroaryl compounds as protein kinase inhibitors
EP1643836A4 (en)	2003-07-02	2006-12-06	Sugen Inc	ARYLMETHYL TRIAZOLO AND IMIDAZOPYRAZINE C-MET INHIBITORS
WO2005005378A2 (en)	2003-07-02	2005-01-20	Sugen, Inc.	Indolinone hydrazides as c-met inhibitors
US7037909B2 (en)	2003-07-02	2006-05-02	Sugen, Inc.	Tetracyclic compounds as c-Met inhibitors
US7122548B2 (en)	2003-07-02	2006-10-17	Sugen, Inc.	Triazolotriazine compounds and uses thereof
DE602004010680T2 (de)	2003-07-30	2009-01-02	Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat	Substituierte imidazopyrimidine zur prävention und behandlung von krebs
AR045595A1 (es)	2003-09-04	2005-11-02	Vertex Pharma	Composiciones utiles como inhibidores de proteinas quinasas
CA2539726A1 (en)	2003-09-24	2005-05-06	Vertex Pharmaceuticals Incorporated	4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
EP2609919A3 (en)	2003-09-26	2014-02-26	Exelixis, Inc.	c-Met modulators and methods of use
US7144889B2 (en)	2003-10-16	2006-12-05	Hoffman-La Roche Inc.	Triarylimidazoles
US7169781B2 (en)	2003-10-17	2007-01-30	Hoffmann-La Roche Inc.	Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en)	2003-10-27	2003-12-03	Novartis Ag	Organic compounds
TW200536851A (en)	2004-01-23	2005-11-16	Amgen Inc	Compounds and methods of use
AU2005207946A1 (en)	2004-01-23	2005-08-11	Amgen Inc.	Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
JPWO2005077953A1 (ja)	2004-02-18	2007-10-18	萬有製薬株式会社	含窒素縮合ヘテロ芳香環誘導体
AP2139A (en)	2004-04-02	2010-08-21	Osi Pharm Inc	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
US20050277650A1 (en)	2004-04-20	2005-12-15	Sundaram Venkataraman	Process for preparing aripirazole hydrate
AU2005245386B2 (en)	2004-05-07	2008-11-27	Amgen Inc.	Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2005121125A1 (en)	2004-06-09	2005-12-22	Pfizer Inc.	Ether-linked heteroaryl compounds
CA2572331A1 (en)	2004-07-02	2006-02-09	Exelixis, Inc.	C-met modulators and method of use
MY139689A (en) *	2004-07-20	2009-10-30	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
AP2373A (en)	2004-08-26	2012-03-07	Pfizer	Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
US7456289B2 (en)	2004-12-31	2008-11-25	National Health Research Institutes	Anti-tumor compounds
WO2006076575A2 (en)	2005-01-13	2006-07-20	Bristol-Myers Squibb Company	Substituted biaryl compounds as factor xia inhibitors
AU2006247833A1 (en)	2005-05-12	2006-11-23	Merck & Co., Inc.	Tyrosine kinase inhibitors
EP1904501A2 (en)	2005-07-11	2008-04-02	Smithkline Beecham Corporation	Chemical compounds
WO2007015866A2 (en)	2005-07-20	2007-02-08	Kalypsys, Inc.	Inhibitors of p38 kinase and methods of treating inflammatory disorders
US20100216798A1 (en)	2005-07-29	2010-08-26	Astellas Pharma Inc	Fused heterocycles as lck inhibitors
US20070049591A1 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) *	2005-09-22	2007-04-05	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
NZ568666A (en) *	2005-11-30	2011-09-30	Vertex Pharma	[1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
CA2634721C (en)	2005-12-21	2014-06-17	Janssen Pharmaceutica N.V.	Triazolopyridazines as tyrosine kinase modulators
LT2495016T (lt) *	2005-12-23	2020-02-10	Ariad Pharmaceuticals, Inc.	Bicikliniai heteroarilų junginiai
WO2007096764A2 (en)	2006-02-27	2007-08-30	Glenmark Pharmaceuticals S.A.	Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US8217177B2 (en) *	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) *	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
CA2660836A1 (en) *	2006-08-07	2008-02-21	Incyte Corporation	Triazolotriazines as kinase inhibitors
JP2010519174A (ja) *	2006-09-18	2010-06-03	バーテックスファーマシューティカルズインコーポレイテッド	ｃ−Ｍｅｔの複素環阻害薬およびその使用方法
MX2009004060A (es) *	2006-10-23	2009-06-19	Sgx Pharmaceuticals Inc	Moduladores de proteina cinasa de triazolpiridazina.
AU2007316417B2 (en)	2006-11-06	2013-08-22	Tolero Pharmaceuticals, Inc.	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
DK3034075T3 (en) *	2006-11-22	2018-10-22	Incyte Holdings Corp	IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASEI INHIBITORS
EP2162132A4 (en)	2007-05-21	2013-01-16	Sgx Pharmaceuticals Inc	Heterocyclic kinase modulators
LT2300455T (lt)	2008-05-21	2017-11-10	Incyte Holdings Corporation	2-fluor-n-metil-4-[7-(chinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamido druskos ir su jų gamyba susiję būdai
MX2012008898A (es)	2010-02-03	2012-11-06	Incyte Corp	Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.

2009
- 2009-05-20 LT LTEP09751439.2T patent/LT2300455T/lt unknown
- 2009-05-20 WO PCT/US2009/044622 patent/WO2009143211A2/en active Application Filing
- 2009-05-20 MX MX2010012718A patent/MX2010012718A/es active IP Right Grant
- 2009-05-20 BR BRPI0912882A patent/BRPI0912882A2/pt not_active Application Discontinuation
- 2009-05-20 EP EP17172014.7A patent/EP3287449A3/en not_active Withdrawn
- 2009-05-20 CN CN200980123120.8A patent/CN102083814B/zh active Active
- 2009-05-20 CA CA2724742A patent/CA2724742C/en active Active
- 2009-05-20 MY MYPI2010005346A patent/MY155565A/en unknown
- 2009-05-20 KR KR1020107028754A patent/KR101706784B1/ko active IP Right Grant
- 2009-05-20 EP EP09751439.2A patent/EP2300455B1/en active Active
- 2009-05-20 MY MYPI2014001739A patent/MY187131A/en unknown
- 2009-05-20 NZ NZ589622A patent/NZ589622A/xx unknown
- 2009-05-20 PT PT97514392T patent/PT2300455T/pt unknown
- 2009-05-20 CN CN202110581794.5A patent/CN113248510B/zh active Active
- 2009-05-20 DK DK09751439.2T patent/DK2300455T3/en active
- 2009-05-20 ES ES09751439.2T patent/ES2643363T3/es active Active
- 2009-05-20 HU HUE09751439A patent/HUE034716T2/hu unknown
- 2009-05-20 PL PL09751439T patent/PL2300455T3/pl unknown
- 2009-05-20 TW TW98116761A patent/TWI472529B/zh active
- 2009-05-20 CN CN201410110793.2A patent/CN103936743B/zh active Active
- 2009-05-20 EA EA201071337A patent/EA021364B1/ru not_active IP Right Cessation
- 2009-05-20 MX MX2013009914A patent/MX368802B/es unknown
- 2009-05-20 US US12/469,360 patent/US8420645B2/en active Active
- 2009-05-20 CN CN201810253971.5A patent/CN108586463A/zh active Pending
- 2009-05-20 NZ NZ602791A patent/NZ602791A/en unknown
- 2009-05-20 CL CL2009001250A patent/CL2009001250A1/es unknown
- 2009-05-20 JP JP2011510669A patent/JP6022158B2/ja active Active
- 2009-05-20 SI SI200931744T patent/SI2300455T1/sl unknown
- 2009-05-20 MY MYPI2018000893A patent/MY199552A/en unknown
- 2009-05-21 AR ARP090101835A patent/AR071873A1/es not_active Application Discontinuation
2010
- 2010-11-10 IL IL209229A patent/IL209229A/en active IP Right Grant
- 2010-11-16 ZA ZA2010/08212A patent/ZA201008212B/en unknown
- 2010-11-19 MX MX2019011954A patent/MX2019011954A/es unknown
- 2010-11-26 CO CO10149434A patent/CO6300934A2/es active IP Right Grant
- 2010-12-16 EC EC2010010685A patent/ECSP10010685A/es unknown
- 2010-12-20 MA MA33445A patent/MA32405B1/fr unknown
2013
- 2013-03-11 US US13/793,864 patent/US8901123B2/en active Active
- 2013-11-04 IL IL229229A patent/IL229229A/en active IP Right Grant
2014
- 2014-10-28 US US14/525,381 patent/US20150148348A1/en not_active Abandoned
2015
- 2015-03-02 JP JP2015040617A patent/JP6105653B2/ja active Active
2016
- 2016-11-18 US US15/355,630 patent/US10245265B2/en active Active
- 2016-12-19 IL IL249651A patent/IL249651A/en active IP Right Grant
2017
- 2017-10-10 HR HRP20171528TT patent/HRP20171528T1/hr unknown
- 2017-10-18 CY CY20171101085T patent/CY1119813T1/el unknown
2018
- 2018-04-26 AR ARP180101072A patent/AR111428A2/es active IP Right Grant
- 2018-08-28 HK HK18111067.5A patent/HK1251568A1/zh unknown
2019
- 2019-02-07 US US16/269,871 patent/US10799509B2/en active Active
2020
- 2020-09-08 US US17/014,414 patent/US11452726B2/en active Active
2021
- 2021-08-12 AR ARP210102275A patent/AR123240A2/es unknown
2022
- 2022-08-18 US US17/820,779 patent/US20230098850A1/en active Pending

Also Published As

Publication number	Publication date
CN113248510B (zh)	2025-01-17
AR071873A1 (es)	2010-07-21
US20210128568A1 (en)	2021-05-06
DK2300455T3 (en)	2017-10-30
CN102083814B (zh)	2014-04-23
JP2015145378A (ja)	2015-08-13
EA021364B1 (ru)	2015-06-30
EP3287449A2 (en)	2018-02-28
IL249651A (en)	2017-10-31
HK1251568A1 (zh)	2019-02-01
HRP20171528T1 (hr)	2017-11-17
CN103936743A (zh)	2014-07-23
CA2724742A1 (en)	2009-11-26
CY1119813T1 (el)	2018-06-27
IL249651A0 (en)	2017-02-28
CL2009001250A1 (es)	2010-02-05
TWI472529B (zh)	2015-02-11
TW201008943A (en)	2010-03-01
EA201071337A1 (ru)	2011-06-30
ES2643363T3 (es)	2017-11-22
PT2300455T (pt)	2017-10-19
US20170258800A1 (en)	2017-09-14
KR20110037962A (ko)	2011-04-13
US20150148348A1 (en)	2015-05-28
MA32405B1 (fr)	2011-06-01
CN103936743B (zh)	2018-04-24
WO2009143211A3 (en)	2010-03-04
MY199552A (en)	2023-11-07
EP3287449A3 (en)	2018-05-30
MY155565A (en)	2015-10-30
CA2724742C (en)	2016-07-19
US8420645B2 (en)	2013-04-16
US20190167692A1 (en)	2019-06-06
EP2300455B1 (en)	2017-07-19
CN108586463A (zh)	2018-09-28
JP6022158B2 (ja)	2016-11-09
CN113248510A (zh)	2021-08-13
JP2011520976A (ja)	2011-07-21
US10799509B2 (en)	2020-10-13
EP2300455A2 (en)	2011-03-30
US10245265B2 (en)	2019-04-02
MY187131A (en)	2021-09-02
NZ602791A (en)	2014-04-30
US20130289036A1 (en)	2013-10-31
AR111428A2 (es)	2019-07-10
US8901123B2 (en)	2014-12-02
AU2009249154B2 (en)	2014-12-11
MX2019011954A (es)	2019-10-30
PL2300455T3 (pl)	2018-02-28
IL229229A (en)	2017-05-29
KR101706784B1 (ko)	2017-02-14
CN102083814A (zh)	2011-06-01
AR123240A2 (es)	2022-11-09
BRPI0912882A2 (pt)	2017-05-16
IL209229A0 (en)	2011-01-31
HUE034716T2 (hu)	2018-02-28
US20090291956A1 (en)	2009-11-26
SI2300455T1 (sl)	2017-12-29
US20230098850A1 (en)	2023-03-30
MX2010012718A (es)	2011-04-04
JP6105653B2 (ja)	2017-03-29
IL209229A (en)	2015-11-30
US11452726B2 (en)	2022-09-27
WO2009143211A2 (en)	2009-11-26
ZA201008212B (en)	2014-04-30
ECSP10010685A (es)	2011-04-29
MX368802B (es)	2019-10-17
AU2009249154A1 (en)	2009-11-26
CO6300934A2 (es)	2011-07-21
NZ589622A (en)	2012-10-26
IL229229A0 (en)	2013-12-31

Publication	Publication Date	Title
HK1251568A1 (zh)	2019-02-01	2-氟基-n-甲基-4-[7-(喹啉-6-基甲基)-咪唑[1，2-b][1，2，4]三嗪-2-基]苯甲酰胺鹽和與其製造相關的步驟
IL257410A (en)	2018-04-30	Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents
HK1178539A1 (zh)	2013-09-13	-環烷基- -二氫-吡唑並嘧啶- -酮衍生物及其作為抑制劑的用途
ZA201304646B (en)	2014-12-23	5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
IL219424A0 (en)	2012-06-28	IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
IL214436A0 (en)	2011-09-27	1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
HK1183029A1 (zh)	2013-12-13	作為調節劑的吡唑並嘧啶和噻吩並嘧啶衍生物
ZA201306719B (en)	2015-04-29	3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace)
IL227526A0 (en)	2013-09-30	Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors
ZA201403441B (en)	2015-08-26	[1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
IL229993A0 (en)	2014-01-30	A process for the preparation of 8-Alkoxy[1,2,4]triazolo[5,1-c]pyrimidine-2 amines 5-converted
PT2448940E (pt)	2014-09-03	Derivados de 6,7,8,9-tetra-hidro-pirimido{1,2-α} pirimidin- 4-ona, sua preparação e sua utilização farmacêutica
PT2448939T (pt)	2017-06-12	Derivados de 2,3-dihidro-1h-imidazo{1,2-a}pirimidin-5-ona, sua preparação e sua utilização farmacêutica
IL216794A0 (en)	2012-02-29	3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use
IL219116A (en)	2016-05-31	5h– oxo- (Theo / oxa) Zulu [a – 2,3] ortho-compressed pyrimidine with other rings and their use for treating anemia and tissue damage caused by ischemic diseases
EP2523552A4 (en)	2013-06-19	PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER
IL220448A (en)	2015-04-30	Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
ZA201008178B (en)	2013-04-24	Imidazo [2,1-b]quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
IL215521A0 (en)	2011-12-29	DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES